Beijing Danatlas Pharmaceutical Technology patents new PARG inhibitors
Nov. 25, 2024
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.